GlycineB antagonists and partial agonists in rodent models of Parkinson’s disease—comparison with uncompetitive N-methyl-d-aspartate receptor antagonist-Reference-Cited by-同舟云学术

GlycineB antagonists and partial agonists in rodent models of Parkinson’s disease—comparison with uncompetitive N-methyl-d-aspartate receptor antagonist

Published:1999-01 Issue:1 Volume:38 Page:109-119
ISSN:0028-3908
Container-title:Neuropharmacology
language:en
Short-container-title:Neuropharmacology

Author:

Karcz-Kubicha M.,Lorenz B.,Danysz W.

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Pharmacology

Reference60 articles.

1. Drugs acting at the strychnine-insensitive glycine receptor do not induce HSP-70 protein in the cingulate cortex;Berger;Neurosci. Lett.,1994

2. The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, l-701,324, in rodents;Bristow;J. Pharmacol. Exp. Ther.,1996

3. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice;Carlsson;J. Neural Transm.,1989

4. Interaction between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson’s disease;Carlsson;Trends Neurosci.,1990

5. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms;Carroll;Psychopharmacology,1995

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Translational molecular imaging and drug development in Parkinson’s disease;Molecular Neurodegeneration;2023-02-10

2. Are ion channels potential therapeutic targets for Parkinson’s disease?;NeuroToxicology;2021-12

3. Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies;European Journal of Neuroscience;2021-04-25

4. Glutamate in Parkinson's disease: Role of antiglutamatergic drugs;Basal Ganglia;2013-12

5. CHAPTER 10. Glutamate Receptor Modulators as Emergent Therapeutic Agents in the Treatment of Parkinson’s Disease;Drug Discovery;2013